UK markets closed

Centessa Pharmaceuticals Limited (CNTA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
12.72-0.03 (-0.24%)
At close: 04:00PM EST
12.72 0.00 (0.00%)
After hours: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close12.75
Bid12.70 x 800
Ask13.98 x 1000
Day's range12.44 - 13.83
52-week range10.50 - 26.90
Avg. volume217,746
Market cap1.144B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Centessa Pharmaceuticals Announces Third Quarter 2021 Financial Results and Business Updates

    ~ Announced positive topline data from proof-of-concept study of SerpinPC in severe hemophilia A and B subjects not on prophylaxis, demonstrating 88% reduction in median Annualized Bleeding Rate (“ABR”) for all bleeds and 94% reduction in median ABR for spontaneous joint bleeds in highest dose tested ~ ~ Announced proof-of-mechanism data from first three PiMZ subjects dosed in Phase 1 Part B study evaluating ZF874 for the treatment of Alpha-1 Antitrypsin Deficiency (“AATD”) ~ ~ Announced collabo

  • Globe Newswire

    Centessa Pharmaceuticals to Present at Upcoming Conferences in 2021

    BOSTON and LONDON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Company”) (Nasdaq: CNTA) today announced that Saurabh Saha, MD, PhD, Chief Executive Officer, will present at the following investor conferences: Event: Jefferies London Healthcare Conference Date: Thursday, November 18, 2021Presentation Details: Recording available on-demand on Thursday, November 18, 2021, starting at 3:00 AM ET (8:00 GMT) Event: Evercore ISI HealthCONx Conference Date: Thursday, December 2, 202

  • Globe Newswire

    Centessa Pharmaceuticals Demonstrates Proof-of-Mechanism from First Three PiMZ Subjects Dosed in Part B of Phase 1 Study Evaluating ZF874

    ~ First demonstration that a pharmacological chaperone can provide sufficient functional Z-A1AT increases to potentially achieve greater than 11 micromolar levels in individuals with PiZZ genotype ~ ~ One subject with two-fold higher exposure experienced reversible ALT and AST elevations ~ ~ Several actions underway to accelerate enrollment to refine dose and regimen for Phase 2 study expected to start in 2Q 2022 ~ ~ Conference call and webcast scheduled for today at 8:30 a.m. EDT ~ BOSTON and L